Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer.

Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis.

A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC).

Beijing Jingwei-Yankang Biomedical Co. Ltd. has reported new phenyl-substituted heterocyclic compounds acting as retinol-binding protein 4 (RBP4) inhibitors with potential in the treatment of age-related macular degeneration (AMD).

KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases.

Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum.

Nurix Therapeutics Inc. has disclosed new proteolysis targeting chimera (PROTAC) compounds potentially useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) modulators potentially useful for the treatment of solid tumors and hematological cancers.

China Pharmaceutical University has patented new isochromanone compounds acting as proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors. As such, they are described as potentially useful for the treatment of atherosclerosis, obesity, hepatic steatosis, hypercholesterolemia, hyperlipidemia and hypertriglyceridemia.

Spark Biopharma Inc. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists potentially useful for the treatment of cancer.